## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.01 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (49% of avg), momentum weakening (-2.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($185.92)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. BD and ChemoGLO™ Collaborate to Expand Hazardous Drug Contamination Testing for Health Care Facilities and Laboratories**
- Source: Becton Dickinson | 20251204T230758 | Bullish | Relevance: 100%
- BD (Becton, Dickinson and Company) and ChemoGLO™ have announced a strategic collaboration to enhance hazardous drug contamination testing in healthcare settings. This partnership allows healthcare facilities to combine BD's rapid, point-of-care qualitative results from the BD® HD Check System with ChemoGLO™'s comprehensive quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. The collaboration aims to improve health care worker safety by providing streamlined sampling and testing workflows to monitor contamination more effectively.

**2. BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes**
- Source: Becton Dickinson | 20251204T060814 | Bullish | Relevance: 100%
- BD (Becton, Dickinson and Company) has launched new configurations of its BD FACSDiscover™ A8 Cell Analyzers, making advanced spectral and real-time imaging cell analysis capabilities more accessible to a wider range of laboratories. These new three- and four-laser instruments, which complement an existing five-laser model, enable scientists to analyze numerous cell characteristics and obtain spatial and morphological insights in real time. The initiative aims to support discoveries in fields like immunology and cancer immunotherapy by providing flexible technology options.

**3. There May Be Reason For Hope In Becton Dickinson's (NYSE:BDX) Disappointing Earnings**
- Source: Yahoo Finance Singapore | 20251203T140200 | Somewhat-Bullish | Relevance: 100%
- Becton Dickinson's recent weak earnings may be understated due to a significant impact from unusual items totalling US$1.3 billion, which are often one-off in nature. If these expenses don't recur, the company's profitability is expected to improve in the next year. The article suggests that Becton Dickinson's statutory profit likely understates its true earnings potential, especially given a 7.6% annual EPS growth over the last three years.

**4. BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes**
- Source: PR Newswire | 20251203T115000 | Bullish | Relevance: 100%
- BD (Becton, Dickinson and Company) announced the global commercial release of new configurations for its BD FACSDiscover™ A8 Cell Analyzers. These new three- and four-laser instruments expand accessibility to breakthrough spectral and real-time imaging cell analysis, enabling more labs in academia, pharma, and biotech to advance discoveries in immunology, cancer immunotherapy, and cell biology. The analyzers feature BD SpectralFX™ Technology for analyzing 50+ cell characteristics and BD CellView™ Image Technology for high-speed imaging, with flexible upgrade options and financing available.

**5. BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes**
- Source: BD Newsroom | 20251203T101255 | Bullish | Relevance: 100%
- BD has globally released new configurations of its FACSDiscover A8 Cell Analyzers, featuring BD SpectralFX and BD CellView Image technologies. These additions, including three- and four-laser options, aim to make cutting-edge spectral and real-time imaging cell analysis more accessible to academic, pharma, and biotech labs of all sizes and budgets. The technology enhances discovery in immunology, cancer immunotherapy, and cell biology by allowing analysis of up to 50 cellular characteristics and providing real-time spatial and morphological insights.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |
| 2025-11-07 | RBC Capital | $202 | $211 | -4% |
| 2025-11-07 | Piper Sandler | $190 | $200 | -5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-07 | RBC Capital | main | Sector Perform |
| 2025-11-07 | Piper Sandler | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($0.04M) |
| Sells | 5 ($0.06M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Balance sheet: $2.7B free cash flow. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.0B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 12.2 |
| Current P/E | 13.0 |
| YoY Growth | 6.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.1% to -0.3% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.3pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.1%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. Volume at 49% of 20MA suggests lack of conviction. OFD pattern: -DLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.29% (CS: 49) | Neutral |
| RSI_14 | 57.8 | Neutral |
| MACD Histogram | 0.19 | Bullish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 1.032x | Above |
| vs SMA200 | 1.012x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $193.76
- **Stop Loss:** $185.92 (4.0% risk)
- **Target:** $209.44 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 63
- **Position Value:** $12,206.88
- **Portfolio %:** 12.21%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*